1-17 of 17
Daniel L. Gustafson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Available to Purchase
Seth P. Lerner, David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua, Siamak Daneshmand, Ajjai Shivaram Alva, M. Scott Lucia, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Woonyoung Choi, Rick Bangs, Daniel L. Gustafson, Melissa Plets, Ian M. Thompson, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 444–449.
https://doi.org/10.1158/1078-0432.CCR-23-0602
Published: 17 January 2024
View articletitled, Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Open the PDF for Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma

Open Access
Daniel P. Regan, Lyndah Chow, Sunetra Das, Laurel Haines, Eric Palmer, Jade N. Kurihara, Jonathan W. Coy, Alissa Mathias, Douglas H. Thamm, Daniel L. Gustafson, Steven W. Dow
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 662–676.
https://doi.org/10.1158/1078-0432.CCR-21-2105
Published: 15 February 2022
View articletitled, Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Open the PDF for Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma in another window
Includes: Supplementary data
Journal Articles

Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Free
Amy K. LeBlanc, Christina N. Mazcko, Aswini Cherukuri, Erika P. Berger, William C. Kisseberth, Megan E. Brown, Susan E. Lana, Kristen Weishaar, Brian K. Flesner, Jeffrey N. Bryan, David M. Vail, Jenna H. Burton, Jennifer L. Willcox, Anthony J. Mutsaers, J. Paul Woods, Nicole C. Northrup, Corey Saba, Kaitlin M. Curran, Haley Leeper, Heather Wilson-Robles, Brandan G. Wustefeld-Janssens, Stephanie Lindley, Annette N. Smith, Nikolaos Dervisis, Shawna Klahn, Mary Lynn Higginbotham, Raelene M. Wouda, Erika Krick, Jennifer A. Mahoney, Cheryl A. London, Lisa G. Barber, Cheryl E. Balkman, Angela L. McCleary-Wheeler, Steven E. Suter, Olya Martin, Antonella Borgatti, Kristine Burgess, Michael O. Childress, Janean L. Fidel, Sara D. Allstadt, Daniel L. Gustafson, Laura E. Selmic, Chand Khanna, Timothy M. Fan
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (11): 3005–3016.
https://doi.org/10.1158/1078-0432.CCR-21-0315
Published: 01 June 2021
View articletitled, Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
Open the PDF for Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Available to Purchase
Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia, David J. McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared S. Fowles, Daniel L. Gustafson, Melissa Plets, Ian M. Thompson, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2435–2441.
https://doi.org/10.1158/1078-0432.CCR-20-2409
Published: 01 May 2021
View articletitled, A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)
Open the PDF for A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) in another window
Includes: Supplementary data
Journal Articles

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors

Available to Purchase
S. Lindsey Davis, Anastasia A. Ionkina, Stacey M. Bagby, James D. Orth, Brian Gittleman, Joshua M. Marcus, Elaine T. Lam, Bradley R. Corr, Cindy L. O'Bryant, Ashley E. Glode, Aik-Choon Tan, Jihye Kim, John J. Tentler, Anna Capasso, Kyrie L. Lopez, Daniel L. Gustafson, Wells A. Messersmith, Stephen Leong, S. Gail Eckhardt, Todd M. Pitts, Jennifer R. Diamond
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4633–4642.
https://doi.org/10.1158/1078-0432.CCR-19-3498
Published: 01 September 2020
View articletitled, Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
Open the PDF for Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo

Free
James J. Morrow, Arnulfo Mendoza, Allyson Koyen, Michael M. Lizardo, Ling Ren, Timothy J. Waybright, Ryan J. Hansen, Daniel L. Gustafson, Ming Zhou, Timothy M. Fan, Peter C. Scacheri, Chand Khanna
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6129–6141.
https://doi.org/10.1158/1078-0432.CCR-16-0326
Published: 15 December 2016
View articletitled, mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo
Open the PDF for mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo in another window
Includes: Supplementary data
Journal Articles

Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer

Free
Anna Spreafico, John J. Tentler, Todd M. Pitts, Aik Choon Tan, Mark A. Gregory, John J. Arcaroli, Peter J. Klauck, Martine C. McManus, Ryan J. Hansen, Jihye Kim, Lindsey N. Micel, Heather M. Selby, Timothy P. Newton, Kelly L. McPhillips, Daniel L. Gustafson, James V. DeGregori, Wells A. Messersmith, Robert A. Winn, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4149–4162.
https://doi.org/10.1158/1078-0432.CCR-12-3140
Published: 31 July 2013
View articletitled, Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Open the PDF for Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A56: Canine Mast Cell Tumor and Toceranib Phosphate (Palladia™): Development of a Spontaneous Canine Model of Kinase Inhibitor Resistance

Free
Charles H.C. Halsey, Barbara J. Rose, Daniel L. Gustafson, Douglas H. Thamm
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A56.
https://doi.org/10.1158/1078-0432.MECHRES-A56
Published: 04 March 2013
View articletitled, Abstract A56: Canine Mast Cell Tumor and Toceranib Phosphate (Palladia™): Development of a Spontaneous Canine Model of Kinase Inhibitor Resistance
Open the PDF for Abstract A56: Canine Mast Cell Tumor and Toceranib Phosphate (Palladia™): Development of a Spontaneous Canine Model of Kinase Inhibitor Resistance in another window
Journal Articles

Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer

Free
Erica L. Bradshaw-Pierce, Todd M. Pitts, Kelly L. McPhillips, Daniel L. Gustafson, Aik-Choon Tan, Leslie Nguyen, Mark West, Timothy Fisher, Brion W. Murray, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A46.
https://doi.org/10.1158/1078-0432.MECHRES-A46
Published: 04 March 2013
View articletitled, Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer
Open the PDF for Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer in another window
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

Free
Jennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt, Eunice L. Kwak, Shuchi S. Pandya, Graham C. Fletcher, Todd M. Pitts, Gillian N. Kulikowski, Mark Morrow, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Wells Messersmith, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 849–860.
https://doi.org/10.1158/1078-0432.CCR-10-2144
Published: 15 February 2011
View articletitled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer

Free
Luke A. Wittenburg, Daniel L. Gustafson, Douglas H. Thamm
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19): 4832–4842.
https://doi.org/10.1158/1078-0432.CCR-10-1238
Published: 29 September 2010
View articletitled, Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer in another window
Journal Articles

Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase I Evaluation

Free
Douglas H. Thamm, Ilene D. Kurzman, Mike A. Clark, E.J. Ehrhart, III, Susan L. Kraft, Daniel L. Gustafson, David M. Vail
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1498–1508.
https://doi.org/10.1158/1078-0432.CCR-09-2804
Published: 28 February 2010
View articletitled, Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase I Evaluation
Open the PDF for Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase I Evaluation in another window
Journal Articles

Letter to the Editor

Free
Daniel L. Gustafson, S. Gail Eckhardt, Erica L. Bradshaw-Pierce
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (24): 7522.
https://doi.org/10.1158/1078-0432.CCR-07-1946
Published: 19 December 2007
View articletitled, Letter to the Editor
Open the PDF for Letter to the Editor in another window
Journal Articles

Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model

Free
Teresa Troiani, Natalie J. Serkova, Daniel L. Gustafson, Thomas K. Henthorn, Owen Lockerbie, Andrea Merz, Michael Long, Mark Morrow, Fortunato Ciardiello, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6450–6458.
https://doi.org/10.1158/1078-0432.CCR-07-1094
Published: 01 November 2007
View articletitled, Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model
Open the PDF for Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model in another window
Journal Articles

A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man

Free
Erica L. Bradshaw-Pierce, S. Gail Eckhardt, Daniel L. Gustafson
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (9): 2768–2776.
https://doi.org/10.1158/1078-0432.CCR-06-2362
Published: 01 May 2007
View articletitled, A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man
Open the PDF for A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man in another window
Journal Articles

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

Free
Michele Basche, Daniel L. Gustafson, Scott N. Holden, Cindy L. O'Bryant, Lia Gore, Samir Witta, Mary Kay Schultz, Mark Morrow, Adrah Levin, Brian R. Creese, Michael Kangas, Kaye Roberts, Thu Nguyen, Kat Davis, Russell S. Addison, Jane C. Moore, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5471–5480.
https://doi.org/10.1158/1078-0432.CCR-05-2423
Published: 25 September 2006
View articletitled, A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors

Free
Samir E. Witta, Daniel L. Gustafson, A. Scott Pierson, Alexander Menter, Scott N. Holden, Michele Basche, Martha Persky, Cindy L. O’Bryant, Chan Zeng, Anna Baron, Michael E. Long, Amy Gibbs, Karen Kelly, Paul A. Bunn, Jr., Daniel C. Chan, Patrick Pallansch, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7229–7237.
https://doi.org/10.1158/1078-0432.CCR-03-0181
Published: 08 November 2004
View articletitled, A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors
Open the PDF for A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors in another window